BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Gentronix Limited Launches Bluescreen HC And Expands Services With Comet Assay Testing


3/29/2010 2:21:41 PM

Manchester, UK - Gentronix has launched its innovative early genotoxicity screening assay BlueScreen HC and an in vitro Comet testing service. Introduced at the recent Society of Toxicology 49th Annual Meeting and ToxExpo in Salt Lake City, these cell-based products and services enable accurate and reliable early identification of compounds likely to induce genotoxic stress and damage. This helps reduce attrition rates in drug discovery and allows the prioritisation of compounds for further development in the R&D pipeline.

BlueScreen HC is a human cell-based reporter assay which requires only low milligram quantities of sample compounds. Providing a simple and effective alternative to fluorescence reporter systems the new Bluescreen HC assay monitors the expression of the P53 linked GADD45a gene, upregulated in response to genotoxic stress. The assay produces a flash luminescent output through the use of the Gaussia luciferase reporter gene.

For ease and speed of use, the BlueScreen HC assay is designed for 96-well microplates, enabling four compounds to be screened in multiple dilutions per plate. Additionally, the assay can be performed with ‘S9’ incubation for the detection of progenotoxins requiring metabolic activation. Available in a kit format, or through Gentronix’s screening service with a turnaround time of just two weeks, the BlueScreen HC assay provides full flexibility of use for drug discovery researchers.

Gentronix has also announced a new in vitro Comet assay service to address the need for fast and accurate genotoxicity testing. Providing insight into the mechanism of genotoxic damage, the Comet assay is an increasingly popular choice to support in vivo studies. The mechanistic information from this reliable in vitro assay can be used to follow up compounds that have produced positive results from GreenScreen HC or Bluescreen HC assays. With a rapid turnaround time and very low compound requirement, the Comet assay service is an efficient and cost-effective method for early identification of compounds likely to exhibit genotoxic liability.

Gentronix now offers a wide range of in vitro genotoxicity screening services, with fast reporting of results and expert support providing a flexible competitive service.

For further information on the BlueScreen HC assay or the in vitro Comet assay service, please email info@gentronix.co.uk, call +44 (0) 161 606 7266, or visit www.gentronix.co.uk

About Gentronix Ltd.:

Gentronix provides services and solutions for a wide range of chemistry-driven industries that help reduce attrition rates and ensure safer products. Gentronix’ primary focus is on providing better hazard identification assays for genotoxicity through its GreenScreen® and BlueScreen™ human cell assay technology. All Gentronix assays are designed for use much earlier in drug and compound discovery than the standard battery of genotoxicity tests, and provide positive results that are more accurately predictive of in vivo risk than the current in vitro mammalian assays. In addition, the high specificity of the assays means that valuable compounds are not discarded due to false positive toxicology.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES